Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Division of General Internal Medicine, Geneva University Hospitals, Rue Gabrielle Perret-Gentil 4, 1211, Geneva 14, Switzerland.
Sci Rep. 2023 Apr 12;13(1):6013. doi: 10.1038/s41598-023-32954-1.
Two successive COVID-19 flares occurred in Switzerland in spring and autumn 2020. During these periods, therapeutic strategies have been constantly adapted based on emerging evidence. We aimed to describe these adaptations and evaluate their association with patient outcomes in a cohort of COVID-19 patients admitted to the hospital. Consecutive patients admitted to the Geneva Hospitals during two successive COVID-19 flares were included. Characteristics of patients admitted during these two periods were compared as well as therapeutic management including medications, respiratory support strategies and admission to the ICU and intermediate care unit (IMCU). A mutivariable model was computed to compare outcomes across the two successive waves adjusted for demographic characteristics, co-morbidities and severity at baseline. The main outcome was in-hospital mortality. Secondary outcomes included ICU admission, Intermediate care (IMCU) admission, and length of hospital stay. A total of 2'983 patients were included. Of these, 165 patients (16.3%, n = 1014) died during the first wave and 314 (16.0%, n = 1969) during the second (p = 0.819). The proportion of patients admitted to the ICU was lower in second wave compared to first (7.4 vs. 13.9%, p < 0.001) but their mortality was increased (33.6% vs. 25.5%, p < 0.001). Conversely, a greater proportion of patients was admitted to the IMCU in second wave compared to first (26.6% vs. 22.3%, p = 0.011). A third of patients received lopinavir (30.7%) or hydroxychloroquine (33.1%) during the first wave and none during second wave, while corticosteroids were mainly prescribed during second wave (58.1% vs. 9.1%, p < 0.001). In the multivariable analysis, a 25% reduction of mortality was observed during the second wave (HR 0.75; 95% confidence interval 0.59 to 0.96). Among deceased patients, 82.3% (78.2% during first wave and 84.4% during second wave) died without beeing admitted to the ICU. The proportion of patients with therapeutic limitations regarding ICU admission increased during the second wave (48.6% vs. 38.7%, p < 0.001). Adaptation of therapeutic strategies including corticosteroids therapy and higher admission to the IMCU to receive non-invasive respiratory support was associated with a reduction of hospital mortality in multivariable analysis, ICU admission and LOS during the second wave of COVID-19 despite an increased number of admitted patients. More patients had medical decisions restraining ICU admission during the second wave which may reflect better patient selection or implicit triaging.
2020 年春季和秋季,瑞士连续发生了两波 COVID-19 疫情。在此期间,根据新出现的证据,治疗策略不断调整。我们旨在描述这些调整,并在一组因 COVID-19 住院的患者中评估其与患者结局的相关性。纳入在两次连续 COVID-19 疫情期间因 COVID-19 住院的连续患者。比较这两个时期入院患者的特征,以及包括药物治疗、呼吸支持策略以及入住 ICU 和中间护理病房(IMCU)在内的治疗管理。计算了多变量模型,以比较根据人口统计学特征、合并症和基线严重程度调整后的两个连续波之间的结局。主要结局是住院死亡率。次要结局包括 ICU 入院、中间护理(IMCU)入院和住院时间。共纳入 2983 名患者。其中,165 名患者(16.3%,n=1014)在第一波中死亡,314 名(16.0%,n=1969)在第二波中死亡(p=0.819)。与第一波相比,第二波入住 ICU 的患者比例较低(7.4%比 13.9%,p<0.001),但死亡率较高(33.6%比 25.5%,p<0.001)。相反,第二波入住 IMCU 的患者比例高于第一波(26.6%比 22.3%,p=0.011)。第一波中有 30.7%的患者接受洛匹那韦或羟氯喹治疗,第二波中没有患者接受治疗,而第二波中主要使用皮质类固醇治疗(58.1%比 9.1%,p<0.001)。多变量分析显示,第二波的死亡率降低了 25%(HR 0.75;95%置信区间 0.59 至 0.96)。在死亡患者中,82.3%(第一波为 78.2%,第二波为 84.4%)未入住 ICU 就死亡。第二波期间,接受 ICU 治疗限制的患者比例增加(48.6%比 38.7%,p<0.001)。包括皮质类固醇治疗和增加 IMCU 入院以接受无创呼吸支持在内的治疗策略的调整,与多变量分析中第二波 COVID-19 住院死亡率、ICU 入院率和 LOS 的降低相关,尽管入住患者人数增加。第二波期间,更多的患者有医疗决策限制 ICU 入院,这可能反映了更好的患者选择或隐含的分诊。